ClinicalTrials.gg
RecruitingNCT07334080Updated Sep 10, 2026

ECC4703 Food Effect and Relative Bioavailability Study in Healthy Adult Participants

A Phase 1 interventional study of ECC4703 F0 formulation and ECC4703 F1 formulation in Metabolic Dysfunction-Associated Steatohepatitis, sponsored by Eccogene. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Eccogene · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Fatty Liver with a site in Australia — 7 open to participants now, 7 under way, 4 of them phase 3. Fatty Liver · Australia.

Planned enrollment
11th of 12
72 · median 260
Started
2026
the only one that year
Phase 1
2 of 14
2 open now
Registered
14th of 14
by date
Lead sponsor
1 of 14
Eccogene

Among the 14 studies in Fatty Liver with a site in Australia, this one is the 11th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2026, is one of 2 in phase 1, and was the 14th registered.

Fatty Liver

663 studies on the registry are indexed under Fatty Liver; 185 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

7 of the 14 studies in Fatty Liver with a site in Australia are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 117 Fatty Liver studies recruiting now, 35 (30%) set no upper age limit and 63 (54%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Fatty Liver with a site in Australia, or all of them as a file.
02

Study summary

This is a Phase I, open-label, randomized, single-dose, 2-part study designed to evaluate the food effect and relative bioavailability of ECC4703 in healthy adult participants.

Read the detailed description

Part 1 will include 3 cohorts of 16 participants each, completing 2 single-dose crossover periods to assess food effect on ECC4703 formulations (F1, F2, and F3). Part 2 of the study will enroll approximately 24 participants to compare selected formulations from Part 1 to formulation (F0), using an adaptive design to finalize sequence, treatment periods, and food conditions.

03

Conditions studied

  • Metabolic Dysfunction-Associated Steatohepatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female participants
  • Age of 18 to 65 years
  • of 18.0 to 32.0 kg/m2 with a minimum body weight of 50.0 kg (110 lb) for males and 45.0 kg (99 lb) for females.
  • Female participants of must have negative serum pregnancy test at screening and a negative serum or urine pregnancy test prior to the first dose of study drug; use at least 1 highly effective method of (e.g., hormonal contraception, intrauterine device, bilateral tubal occlusion, or vasectomized partner with confirmed success) during the study and for at least 90 days after the last dose of study drug; and refrain from egg donation or fertility treatments during the same period.
  • Female participants who are , confirmed by FSH test, or surgically sterile, confirmed by medical documentation, or agree to practice true abstinence
  • Male participants agree to use contraception, or agree to practice true abstinence
  • Not taking any medication within 14 days (or at least 5 half-lives whichever is longer) prior to Day 1 dosing, with the exception of stable-dose contraception, stable-dose hormonal replacement therapy, paracetamol at up to 2 g/day; or other medication, which in the opinion of the investigator and sponsor will not interfere with study assessments.
  • No findings in physical examination, 12-lead (ECG), vital sign measurements, clinical laboratory evaluations, concomitant medications, or medical/psychiatric history
  • Able to understand and sign and date

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant, planning to become pregnant, or breastfeeding during the study or within 90 days after the study.
  • Concomitant participation in any study of any nature
  • Blood loss of ≥470 mL for non-physiological reasons (i.e., trauma, blood collection, blood donation) within 3 months prior to the first dose of study drug, plasma donation within 2 weeks prior to the first dose, donation within 6 weeks prior to the first dose, or plans to donate blood during this study or within 1 month after the last dose of study drug.
  • acute or chronic medical conditions or diseases of the cardiovascular, gastrointestinal, hepatic, renal, endocrine, pulmonary, neurologic, psychiatric, immune or dermatologic systems
  • Significant allergic reaction to active ingredients or of the study drug
  • Regularly uses tobacco or nicotine products, including e-cigarettes (>5 times per week) or has stopped using regular tobacco or nicotine products within the past 2 months.
  • Unwilling to abstain from alcohol-containing products and/or xanthine/caffeine-containing products, including any food and beverages, within 48 hours prior to admission to the CRU on Day -1.
  • Unwilling to abstain from grapefruit, grapefruit juice, and Seville oranges from 7 days prior to check-in on Day -1 until after their final follow-up visit.
  • Unable to refrain from the use of any over-the-counter medications, prescription medications, nutritional supplements, or herbal medicines during the study, except for stable-dose , stable-dose hormonal replacement therapy, paracetamol at up to 2 g/day; or other medication, which in the opinion of the investigator and sponsor will not interfere with study assessments.
  • Any clinically significant abnormal findings in the participant's physical examination, laboratory tests, pregnancy test, urine drug screen, alcohol test, or medical history which in the opinion of the Investigator would prevent the participants from participating in the study.
  • Has had clinically significant interventional therapies and/or hospitalization (surgery, paracentesis, etc.) within 6 months prior to the study, or plans to have any surgeries during the duration of the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    ECC4703 F1 formulation

    Participants will receive a single dose of ECC4703 F1 high-fat or fasted state, followed by ECC4703 F1 fasted or high-fat state, respectively, in subsequent treatment periods

    Drug: ECC4703 F1 formulation

  • Experimental
    ECC4703 F2 formulation

    Participants will receive a single dose of ECC4703 F2 high-fat or fasted state, followed by ECC4703 F2 fasted or high-fat state, respectively, in subsequent treatment periods

    Drug: ECC4703 F2 formulation

  • Experimental
    ECC4703 F3 formulation

    Participants will receive a single dose of ECC4703 F3 high-fat or fasted state, followed by ECC4703 F3 fasted or high-fat state, respectively, in subsequent treatment periods

    Drug: ECC4703 F3 formulation

  • Experimental
    ECC4703 F0 formulation

    Participants will receive a single dose of ECC4703 F0 fasted state, followed by ECC4703 F1, F2 or F3 fasted in subsequent treatment periods

    Drug: ECC4703 F0 formulation · Drug: ECC4703 F1 formulation · Drug: ECC4703 F2 formulation · Drug: ECC4703 F3 formulation

Interventions

06

What researchers measure

Primary outcomes

  1. ECC4703 pharmacokinetic (PK) parameters AUC0-tlast

    Area under the Plasma Concentration-Time Curve from Time 0 to the Last Measurable Non-Zero Concentration

    Time frame: Up to Day 13

  2. ECC4703 PK parameters AUC0-inf

    Area under the Plasma Concentration-Time Curve from Time 0 Extrapolated to Infinity

    Time frame: Up to Day 13

  3. ECC4703 PK parameters Cmax

    Maximum observed plasma concentration

    Time frame: Up to Day 13

  4. ECC4703 PK parameters tmax

    Time of the maximum observed plasma concentration

    Time frame: Up to Day 13

  5. ECC4703 PK parameters AUC0-t

    Area under the plasma concentration-time curve up to the last measurable concentration

    Time frame: Up to Day 13

  6. ECC4703 PK parameters AUC0-24

    Area under the plasma concentration-time curve from time 0 to 24 hours post-dose

    Time frame: Up to Day 13

  7. ECC4703 PK parameters AUCextr

    percentage of area under the concentration-time curve that is due to extrapolation from the last measurable concentration to infinity

    Time frame: Up to Day 13

  8. ECC4703 PK parameters tlag

    lag time (time delay between dosing and first observed plasma concentration)

    Time frame: Up to Day 13

  9. ECC4703 PK parameters t1/2

    elimination half-life

    Time frame: Up to Day 13

  10. ECC4703 PK parameters CL/F

    apparent clearance

    Time frame: Up to Day 13

Secondary outcomes

  1. Number of participants with adverse events, with abnormal laboratory test results, abnormal ECGs, abnormal vital signs, and abnormal physical examinations

    Safety Assessment evaluated through adverse events, laboratory evaluations, vital signs, ECGs, and physical examination

    Time frame: Up to Day 18

  2. ECC4703 PK parameters AUC0-t

    area under the plasma concentration-time curve up to the last measurable concentration

    Time frame: Up to Day 13

  3. ECC4703 PK parameters AUC0-24

    Area under the plasma concentration-time curve from time 0 to 24 hours post-dose

    Time frame: Up to Day 13

  4. ECC4703 PK parameters AUCextr

    percentage of area under the concentration-time curve that is due to extrapolation from the last measurable concentration to infinity

    Time frame: Up to Day 13

  5. ECC4703 PK parameters tlag

    lag time (time delay between dosing and first observed plasma concentration)

    Time frame: Up to Day 13

  6. ECC4703 PK parameters t1/2

    elimination half-life

    Time frame: Up to Day 13

  7. ECC4703 PK parameters CL/F

    apparent clearance

    Time frame: Up to Day 13

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Apr 2027, 15 months after the start.

Of 22 phase 1 interventional studies under Fatty Liver, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2025
First posted
Jan 12, 2026
StartActual
Jan 7, 2026
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07334080
Lead sponsor
Eccogene
Responsible party
Sponsor
First posted
Jan 12, 2026
Start date
Jan 7, 2026
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Sep 10, 2026

Study contacts

Eccogene Clinical Trials
Contact
contact@eccogene.com
86-21-61053022
Eccogene Clinical Trials
study director · Eccogene

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ECC4703

Start the discussion